Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Juliette Morgan is active.

Publication


Featured researches published by Juliette Morgan.


Journal of Clinical Microbiology | 2004

Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program

Rana Hajjeh; Andre N. Sofair; Lee H. Harrison; G. Marshall Lyon; Beth A. Arthington-Skaggs; Sara Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A. Ciblak; Lynette Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E. Brandt; David W. Warnock

ABSTRACT To determine the incidence of Candida bloodstream infections (BSI) and antifungal drug resistance, population-based active laboratory surveillance was conducted from October 1998 through September 2000 in two areas of the United States (Baltimore, Md., and the state of Connecticut; combined population, 4.7 million). A total of 1,143 cases were detected, for an average adjusted annual incidence of 10 per 100,000 population or 1.5 per 10,000 hospital days. In 28% of patients, Candida BSI developed prior to or on the day of admission; only 36% of patients were in an intensive care unit at the time of diagnosis. No fewer than 78% of patients had a central catheter in place at the time of diagnosis, and 50% had undergone surgery within the previous 3 months. Candida albicans comprised 45% of the isolates, followed by C. glabrata (24%), C. parapsilosis (13%), and C. tropicalis (12%). Only 1.2% of C. albicans isolates were resistant to fluconazole (MIC, ≥64 μg/ml), compared to 7% of C. glabrata isolates and 6% of C. tropicalis isolates. Only 0.9% of C. albicans isolates were resistant to itraconazole (MIC, ≥1 μg/ml), compared to 19.5% of C. glabrata isolates and 6% of C. tropicalis isolates. Only 4.3% of C. albicans isolates were resistant to flucytosine (MIC, ≥32 μg/ml), compared to <1% of C. parapsilosis and C. tropicalis isolates and no C. glabrata isolates. As determined by E-test, the MICs of amphotericin B were ≥0.38 μg/ml for 10% of Candida isolates, ≥1 μg/ml for 1.7% of isolates, and ≥2 μg/ml for 0.4% of isolates. Our findings highlight changes in the epidemiology of Candida BSI in the 1990s and provide a basis upon which to conduct further studies of selected high-risk subpopulations.


Journal of Clinical Microbiology | 2005

Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003

Benito Almirante; Dolors Rodríguez; Benjamin J. Park; Manuel Cuenca-Estrella; Ana M. Planes; M. Almela; José Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Giménez; Pere Saballs; Scott K. Fridkin; Juliette Morgan; Juan L. Rodriguez-Tudela; David W. Warnock; Albert Pahissa

ABSTRACT We conducted population-based surveillance for Candida bloodstream infections in Spain to determine its incidence, the extent of antifungal resistance, and risk factors for mortality. A case was defined as the first positive blood culture for any Candida spp. in a resident of Barcelona, from 1 January 2002 to 31 December 2003. We defined early mortality as occurring between days 3 to 7 after candidemia and late mortality as occurring between days 8 to 30. We detected 345 cases of candidemia, for an average annual incidence of 4.3 cases/100,000 population, 0.53 cases/1,000 hospital discharges, and 0.73 cases/10,000 patient-days. Outpatients comprised 11% of the cases, and 89% had a central venous catheter (CVC) at diagnosis. Overall mortality was 44%. Candida albicans was the most frequent species (51% of cases), followed by Candida parapsilosis (23%), Candida tropicalis (10%), Candida glabrata (8%), Candida krusei (4%), and other species (3%). Twenty-four isolates (7%) had decreased susceptibility to fluconazole (MIC ≥ 16 μg/ml). On multivariable analysis, early death was independently associated with hematological malignancy (odds ratio [OR], 3.5; 95% confidence interval [CI], 1.1 to 10.4). Treatment with antifungals (OR, 0.05; 95% CI, 0.01 to 0.2) and removal of CVCs (OR, 0.3; 95% CI, 0.1 to 0.9) were protective factors for early death. Receiving adequate treatment, defined as having CVCs removed and administration of an antifungal medication (OR, 0.2; 95% CI, 0.08 to 0.8), was associated with lower odds of late mortality; intubation (OR, 7.5; 95% CI, 2.6 to 21.1) was associated with higher odds. The incidence of candidemia and prevalence of fluconazole resistance are similar to other European countries, indicating that routine antifungal susceptibility testing is not warranted. Antifungal medication and catheter removal are critical in preventing mortality.


Journal of Clinical Microbiology | 2006

Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers

Arnaldo Lopes Colombo; Marcio Nucci; Benjamin J. Park; Simone Aranha Nouér; Beth A. Arthington-Skaggs; Daniel Archimedes da Matta; David W. Warnock; Juliette Morgan

ABSTRACT Candidemia studies have documented geographic differences in rates and epidemiology, underscoring the need for surveillance to monitor trends. We conducted prospective candidemia surveillance in Brazil to assess the incidence, species distribution, frequency of antifungal resistance, and risk factors for fluconazole-resistant Candida species. Prospective laboratory-based surveillance was conducted from March 2003 to December 2004 in 11 medical centers located in 9 major Brazilian cities. A case of candidemia was defined as the isolation of Candida spp. from a blood culture. Incidence rates were calculated per 1,000 admissions and 1,000 patient-days. Antifungal susceptibility tests were performed by using the broth microdilution assay, according to the Clinical and Laboratory Standards Institute guidelines. We detected 712 cases, for an overall incidence of 2.49 cases per 1,000 admissions and 0.37 cases per 1,000 patient-days. The 30-day crude mortality was 54%. C. albicans was the most common species (40.9%), followed by C. tropicalis (20.9%) and C. parapsilosis (20.5%). Overall, decreased susceptibility to fluconazole occurred in 33 (5%) of incident isolates, 6 (1%) of which were resistant. There was a linear correlation between fluconazole and voriconazole MICs (r = 0.54 and P < 0.001 [Spearmans rho]). This is the largest multicenter candidemia study conducted in Latin America and shows the substantial morbidity and mortality of candidemia in Brazil. Antifungal resistance was rare, but correlation between fluconazole and voriconazole MICs suggests cross-resistance may occur.


Infection Control and Hospital Epidemiology | 2005

Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance.

Juliette Morgan; Martin I. Meltzer; Brian D. Plikaytis; Andre N. Sofair; Sharon Huie-White; Steven Wilcox; Lee H. Harrison; Eric C. Seaberg; Rana Hajjeh; Steven M. Teutsch

OBJECTIVE To determine the mortality, hospital stay, and total hospital charges and cost of hospitalization attributable to candidemia by comparing patients with candidemia with control-patients who have otherwise similar illnesses. Prior studies lack broad patient and hospital representation or cost-related information that accurately reflects current medical practices. DESIGN Our case-control study included case-patients with candidemia and their cost-related data, ascertained from laboratory-based candidemia surveillance conducted among all residents of Connecticut and Baltimore and Baltimore County, Maryland, during 1998 to 2000. Control-patients were matched on age, hospital type, admission year, discharge diagnoses, and duration of hospitalization prior to candidemia onset. RESULTS We identified 214 and 529 sets of matched case-patients and control-patients from the two locations, respectively. Mortality attributable to candidemia ranged between 19% and 24%. On multivariable analysis, candidemia was associated with mortality (OR, 5.3 for Connecticut and 8.5 for Baltimore and Baltimore County; P < .05), whereas receiving adequate treatment was protective (OR, 0.5 and 0.4 for the two locations, respectively; P < .05). Candidemia itself did not increase the total hospital charges and cost of hospitalization; when treatment status was accounted for, having received adequate treatment for candidemia significantly increased the total hospital charges and cost of hospitalization (


Clinical Infectious Diseases | 2002

Outbreak of Leptospirosis among Triathlon Participants and Community Residents in Springfield, Illinois, 1998

Juliette Morgan; Shari L. Bornstein; Adam Karpati; Michael G. Bruce; Carole A. Bolin; Constance C. Austin; Christopher W. Woods; Jairam R. Lingappa; Carl Langkop; Belinda Davis; Donald R. Graham; Mary E. Proctor; David A. Ashford; Mary D. Bajani; Sandra L. Bragg; Kathleen A. Shutt; Bradley A. Perkins; Jordan W. Tappero

6,000 to


Journal of Clinical Microbiology | 2004

Epidemiologic and Molecular Characterization of an Outbreak of Candida parapsilosis Bloodstream Infections in a Community Hospital

Thomas A. Clark; Sally Slavinski; Juliette Morgan; Timothy J. Lott; Beth A. Arthington-Skaggs; Mary E. Brandt; Risa M. Webb; Mary Currier; Richard H. Flowers; Scott K. Fridkin; Rana Hajjeh

29,000 and


Emerging Infectious Diseases | 2002

Automatic Electronic Laboratory-Based Reporting of Notifiable Infectious Diseases

Anil A. Panackal; Fu-Chiang Tsui; Joan McMahon; Michael M. Wagner; Bruce W. Dixon; Juan Zubieta; Maureen Phelan; Sara Mirza; Juliette Morgan; Daniel B. Jernigan; A. William Pasculle; James T. Rankin; Rana Hajjeh; Lee H. Harrison

3,000 to


AIDS | 2006

Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence.

Kerrigan M McCarthy; Juliette Morgan; Kathleen Wannemuehler; Sara Mirza; Susan Gould; Ntombi Mhlongo; Portia Moeng; Bonnie R Maloba; Heather H. Crewe-Brown; Mary E. Brandt; Rana Hajjeh

22,000, respectively) and the length of stay (3 to 13 days). CONCLUSION Our findings underscore the burden of candidemia, particularly regarding the risk of death, length of hospitalization, and cost associated with treatment.


Clinical Infectious Diseases | 2006

Cryptococcus gattii Infection: Characteristics and Epidemiology of Cases Identified in a South African Province with High HIV Seroprevalence, 2002–2004

Juliette Morgan; Kerrigan McCarthy; Susan Gould; Ke Fan; Beth A. Arthington-Skaggs; Naureen Iqbal; Karen Stamey; Rana Hajjeh; Mary E. Brandt

We investigated an outbreak of leptospirosis among athletes and community residents after a triathlon was held in Springfield, Illinois. A telephone survey was conducted to collect clinical information and data on possible risk factors, community surveillance was established, and animal specimens and lake water samples were collected to determine the source of the leptospiral contamination. A total of 834 of 876 triathletes were contacted; 98 (12%) reported being ill. Serum samples obtained from 474 athletes were tested; 52 of these samples (11%) tested positive for leptospirosis. Fourteen (6%) of 248 symptomatic community residents tested positive for leptospirosis. Heavy rains that preceded the triathlon are likely to have increased leptospiral contamination of Lake Springfield. Among athletes, ingestion of 1 or more swallows of lake water was a predominant risk factor for illness. This is the largest outbreak of leptospirosis that has been reported in the United States. Health care providers and occupational and recreational users of bodies of freshwater in the United States should be aware of the risk of contracting leptospirosis, particularly after heavy rains.


Emerging Infectious Diseases | 2004

Coccidioidomycosis among workers at an archeological site, northeastern Utah.

Lyle R. Petersen; Stacie L. Marshall; Christine Barton; Rana Hajjeh; Mark D. Lindsley; David W. Warnock; Anil A. Panackal; Joseph B. Shaffer; Maryam B. Haddad; Frederick S. Fisher; David T. Dennis; Juliette Morgan

ABSTRACT Candida parapsilosis is an important cause of bloodstream infections in the health care setting. We investigated a large C. parapsilosis outbreak occurring in a community hospital and conducted a case-control study to determine the risk factors for infection. We identified 22 cases of bloodstream infection with C. parapsilosis: 15 confirmed and 7 possible. The factors associated with an increased risk of infection included hospitalization in the intensive care unit (adjusted odds ratio, 16.4; 95% confidence interval, 1.8 to 148.1) and receipt of total parenteral nutrition (adjusted odds ratio, 9.2; 95% confidence interval, 0.9 to 98.1). Samples for surveillance cultures were obtained from health care worker hands, central venous catheter insertion sites, and medical devices. Twenty-six percent of the health care workers surveyed demonstrated hand colonization with C. parapsilosis, and one hand isolate was highly related to all case-patient isolates by tests with the DNA probe Cp3-13. Outbreak strain isolates also demonstrated reduced susceptibilities to fluconazole and voriconazole. This largest known reported outbreak of C. parapsilosis bloodstream infections in adults resulted from an interplay of host, environment, and pathogen factors. Recommendations for control measures focused on improving hand hygiene compliance.

Collaboration


Dive into the Juliette Morgan's collaboration.

Top Co-Authors

Avatar

Rana Hajjeh

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Mary E. Brandt

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sara Mirza

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Scott K. Fridkin

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Beth A. Arthington-Skaggs

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maureen Phelan

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Adam Wolkon

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Adeline Chan

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge